|Day Low/High||0.90 / 0.94|
|52 Wk Low/High||0.83 / 2.13|
The company enters a licensing pact with Celgene worth about $27 million.
The biopharmaceutical company says its treatment for blood cancer has shown positive results.
The company says SU5416, one of the first antiangiogenesis drugs, wasn't working.
Three years after an overhyped rollout, drugs that attack tumors' blood supplies are making progress.
GMP boasts an ample supply of biotech stars but little in terms of revenue or product. Is this market ready for this deal?
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.